Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Division of Radiation Oncology, University of Vermont Cancer Center, Burlington, Vermont.
Pract Radiat Oncol. 2021 Jan-Feb;11(1):13-25. doi: 10.1016/j.prro.2020.08.004. Epub 2020 Oct 21.
This guideline reviews the evidence and provides recommendations for the indications and appropriate technique and dose of neoadjuvant radiation therapy (RT) in the treatment of localized rectal cancer.
The American Society for Radiation Oncology convened a task force to address 4 key questions focused on the use of RT in preoperative management of operable rectal cancer. These questions included the indications for neoadjuvant RT, identification of appropriate neoadjuvant regimens, indications for consideration of a nonoperative or local excision approach after chemoradiation, and appropriate treatment volumes and techniques. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength.
Neoadjuvant RT is recommended for patients with stage II-III rectal cancer, with either conventional fractionation with concurrent 5-FU or capecitabine or short-course RT. RT should be performed preoperatively rather than postoperatively. Omission of preoperative RT is conditionally recommended in selected patients with lower risk of locoregional recurrence. Addition of chemotherapy before or after chemoradiation or after short-course RT is conditionally recommended. Nonoperative management is conditionally recommended if a clinical complete response is achieved after neoadjuvant treatment in selected patients. Inclusion of the rectum and mesorectal, presacral, internal iliac, and obturator nodes in the clinical treatment volume is recommended. In addition, inclusion of external iliac nodes is conditionally recommended in patients with tumors invading an anterior organ or structure, and inclusion of inguinal and external iliac nodes is conditionally recommended in patients with tumors involving the anal canal.
Based on currently published data, the American Society for Radiation Oncology task force has proposed evidence-based recommendations regarding the use of RT for rectal cancer. Future studies will look to further personalize treatment recommendations to optimize treatment outcomes and quality of life.
本指南回顾了相关证据,并就局部直肠癌新辅助放疗(RT)的适应证、合适技术和剂量提出了建议。
美国放射肿瘤学会召集了一个工作组,针对 RT 在可手术直肠癌术前管理中的应用这 4 个关键问题进行了讨论。这些问题包括新辅助 RT 的适应证、合适的新辅助方案的选择、放化疗后考虑非手术或局部切除的适应证,以及合适的治疗体积和技术。推荐意见是基于系统文献回顾,并使用预先确定的共识制定方法和证据质量分级以及推荐强度系统制定的。
新辅助 RT 推荐用于 II-III 期直肠癌患者,包括常规分割同期氟尿嘧啶或卡培他滨或短程 RT。RT 应在术前进行,而不是术后进行。在局部复发风险较低的特定患者中,选择性省略术前 RT。在放化疗前、后或短程 RT 后加用化疗被有条件推荐。在特定患者新辅助治疗后获得临床完全缓解时,非手术治疗被有条件推荐。推荐将直肠和中直肠、骶前、髂内和闭孔淋巴结包括在临床治疗体积中。此外,在肿瘤侵犯前器官或结构的患者中,有条件地推荐包括髂外淋巴结,在肿瘤累及肛管的患者中,有条件地推荐包括腹股沟和髂外淋巴结。
基于目前已发表的数据,美国放射肿瘤学会工作组针对直肠癌 RT 的应用提出了基于证据的推荐意见。未来的研究将进一步个性化治疗建议,以优化治疗结果和生活质量。